Argenx Ventures Over $1.5 Billion into UNP's Macrocyclic Peptides Targeting Challenging "Undruggable" Areas

Argenx Ventures Over $1.5 Billion into UNP’s Macrocyclic Peptides Targeting Challenging “Undruggable” Areas